Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH ON: Bivalent Booster Immunogenicity in Healthcare Workers
NCT05471440Phase 4Unknown
- Sponsor
- Erasmus MC
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19), sponsored by Erasmus MC. Status: unknown.
02
Drugs
tozinameranelasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05471440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471440.